Generation Bio to develop iqDNA, discontinue ceDNA development

Generation Bio earlier today announced the development of a novel DNA called immune-quiet DNA. iqDNA is an optimized variant of the company’s closed-ended DNA that upon systemic administration with Generation Bio’s lipid nanoparticle delivery “has shown cytokine levels and tolerability comparable to chemically modified messenger RNA in mice and non-human primates,” the company said in a statement. Generation Bio’s non-viral genetic medicine platform “aims to advance durable, redosable, and titratable therapies to reach potentially hundreds of millions of patients worldwide.” Citing the “superior tolerability profile “of iqDNA, Generation is discontinuing development of prior ceDNA constructs and is advancing iqDNA “as the cargo for its lead program in hemophilia A as well as for all other programs.” Generation Bio believes it has sufficient cash to extend the funding of its operations into 2026 based on income from the Moderna collaboration. Concurrent with extending its cash runway, the company is increasing investment in its iqDNA and ctLNP platform